B Cell Malignancies Clinical Trial
Official title:
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Infusion of Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.
This study is a single-center, open-label, single-dose clinical trial of anti-CD19-CAR-T cell therapy in relapsed/refractory B-cell tumor patients after Qinglin pre-treatment. In this study phase, a traditional "3+3" trial design is employed for dose escalation.
The study plans to include CD19-positive relapsed/refractory B-cell tumor patients. After the screening period, peripheral blood mononuclear cell (PBMC) collection, and lymphocyte depletion pre-treatment period, subjects will receive a single infusion of anti-CD19-CAR-T cells. In addition to the baseline period, efficacy assessments will be conducted monthly for ALL subjects and at weeks 4, 12, 24, 36, and 48 post-treatment for NHL subjects, until disease progression (PD), relapse, change of treatment regimen, death, intolerable toxicity, at the discretion of the investigator, or voluntary withdrawal by the patient (whichever occurs first). Toxicity will be evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE, version 5.0). Safety of anti-CD19-CAR-T cell therapy will be evaluated through laboratory tests, 12-lead electrocardiograms, vital signs, physical examinations, etc. Blood samples will be collected from subjects to assess cellular pharmacokinetics and explore the effects of cellular drugs on ferritin, C-reactive protein, and related cytokines. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05995015 -
4SCAR19U T Cells Targeting B Cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT05436496 -
CD19/70 Bi-specific CAR-T Cell Therapy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05432882 -
CD19/22 Bi-specific CAR-T Cell Therapy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05436509 -
CD19/79b Bi-specific CAR-T Cell Therapy
|
Phase 1/Phase 2 | |
| Terminated |
NCT00672152 -
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation
|
Phase 1 | |
| Recruiting |
NCT05618028 -
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
|
Phase 1 |